BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study-Reference-Cited by-同舟云学术

BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study

Published:2019-11-26 Issue:22 Volume:3 Page:3740-3749
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Zuckerman Tsila¹²,Ram Ron³,Akria Luiza⁴,Koren-Michowitz Maya⁵^ORCID,Hoffman Ron¹²,Henig Israel¹,Lavi Noa¹²,Ofran Yishai¹²^ORCID,Horowitz Netanel A.¹²,Nudelman Olga¹,Tavor Sigal⁶,Yeganeh Shay⁷,Gengrinovitch Stela⁸,Flaishon Liat⁸,Tessler Shoshi⁸,Ben Yakar Ruth⁸,Rowe Jacob M.¹²⁹

Affiliation:

1. Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel;

2. The Ruth and Bruce Rappaport Faculty of Medicine, Technion–Israel Institute of Technology, Haifa, Israel;

3. Hematology Division, Sourasky Medical Center, Tel-Aviv, Israel;

4. Department of Hematology, Galil Medical Center, Nahariya, Israel;

5. Department of Hematology, Assaf Harofeh Medical Center, Zerifin, Israel;

6. Department of Hematology, Assuta Medical Center, Tel Aviv, Israel;

7. Department of Hematology, Poria Medical Center, Tiberias, Israel;

8. BioSight Ltd, Airport City, Lod, Israel; and

9. Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel

Abstract

Key Points The majority of older adults or unfit acute leukemia patients are not offered intensive therapy, resulting in dismal long-term survival. A novel cytarabine prodrug BST-236 enables delivery of high-dose cytarabine and appears to be safe and efficacious in these patients.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/3/22/3740/1543390/advancesadv2019000468.pdf

Reference29 articles.

1. An update of current treatments for adult acute myeloid leukemia;Dombret;Blood,2016

2. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel;Dohner;Blood,2017

3. Cytarabine and neurologic toxicity;Baker;J Clin Oncol,1991

4. Intensive postremission chemotherapy in adults with acute myeloid leukemia;Mayer;N Engl J Med,1994

5. Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia;Harris;Br J Clin Pharmacol,1979

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study;Blood Advances;2023-12-14

2. A novel mesenchymal stem cell-based regimen for acute myeloid leukemia differentiation therapy;Acta Pharmaceutica Sinica B;2023-07

3. Cytarabine induces cachexia with lipid malabsorption via zippering the junctions of lacteal in murine small intestine;Journal of Lipid Research;2023-06

4. Venetoclax in combination with nucleoside analogs in acute myelogenous leukemia;Current Opinion in Oncology;2022-07-16

5. Consolidation in AML: Abundant opinion and much unknown;Blood Reviews;2022-01